Inozyme Pharma Stock (NASDAQ:INZY)

Forecast Ownership Financials Chart

Previous Close

$3.98

52W Range

$0.72 - $6.24

50D Avg

$2.11

200D Avg

$2.87

Market Cap

$256.31M

Avg Vol (3M)

$2.08M

Beta

2.29

Div Yield

INZY Company Profile

Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, as well as for the treatment of calciphylaxis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. Inozyme Pharma, Inc. was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Jul 24, 2020

Website

INZY Performance

INZY Financial Summary

	Dec 24	Dec 23	Dec 22
Revenue	-	-	-
Operating Income	$-104.03M	$-75.64M	$-68.67M
Net Income	$-102.02M	$-71.17M	$-65.45M
EBITDA	$-104.03M	$-74.81M	$-65.88M
Basic EPS	$-1.62	$-1.37	$-1.73
Diluted EPS	$-1.62	$-1.37	$-1.73

Fiscal year ends in Dec 24 | Currency in USD

Peer Comparison

Ticker	Company
TERN	Terns Pharmaceuticals, Inc.
AMLX	Amylyx Pharmaceuticals, Inc.
MREO	Mereo BioPharma Group plc
ELDN	Eledon Pharmaceuticals, Inc.
DAWN	Day One Biopharmaceuticals, Inc.
PDSB	PDS Biotechnology Corporation
XFOR	X4 Pharmaceuticals, Inc.
HOOK	HOOKIPA Pharma Inc.
ABOS	Acumen Pharmaceuticals, Inc.